Surrozen Inc - Warrants (01/08/2026)

Surrozen Inc - Warrants (01/08/2026)

SRZNW

Get informed when a big investor buys or sells

+ Follow
Market Cap$195.98M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Surrozen Inc - Warrants (01/08/2026)Surrozen Inc - Warrants (01/08/2026)-0.8-77%--
$10.83

Current Fair Value

63588.2% upside

Undervalued by 63588.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$195.98 Million
Enterprise Value$95.85 Million
Dividend Yield$- (-)
Earnings per Share$-32.37
Beta0.59
Outstanding Shares10,949,000

Return

Return on Equity77.32%ROE
Return on Assets-178.16%
Return on Invested Capital-93.39%

Valuation & Multiples

P/E Ratio-0.84P/E Ratio
PEG0.84PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.0Price to Book Ratio
Enterprise Value to Revenue12.79
Enterprise Value to EBIT-0.92
Enterprise Value to Net Income-1
Total Debt to Enterprise0.07
Debt to Equity-0.02Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 13, 2026
EPS Estimate
$-1.09
Average shareholder expectation
Revenue Estimate
$4.00 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 6, 2026
EPS Estimate
$-1.29
Average shareholder expectation
Revenue Estimate
$467,250
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls180,8090%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %26.68% 6.89%
Total Invested$46,744 18.78%
Investors Holding18 1.00%

ESG Score

No data

About Surrozen Inc

2,021 employees

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs a...